Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial
Authors' conclusion
Aspirin monotherapy compared with clopidogrel monotherapy was associated with similar cardiovascular and bleeding outcomes beyond 1 month and up to 1 year after percutaneous coronary intervention with drug-eluting stents
Study context
- Population
- Patients with ACS or high bleeding risk after PCI with drug-eluting stentsof 6002 assigned
- Participants
- 5,833 patients
- Comparison
- Aspirin monotherapy vs clopidogrel monotherapy after PCI
- Aspirinn = 2,920
- Clopidogreln = 2,913reference
- Primary endpoint
- Co-primary: CV endpoint (CV death, MI, definite stent thrombosis or ischaemic stroke) and bleeding endpoint (BARC 3 or 5)
- Follow-up
- Beyond 30 days up to 1 year
Methodological details30-day landmark analysis
- 30-day landmark analysis
Primary result
As reported in the abstract
beyond 30 days and up to 1 year
Aspirin
- CV endpoint
- 4.5 per 100 person-year
- Bleeding endpoint
- 2.0
Clopidogrel
- CV endpoint
- 4.5 per 100 person-year
- Bleeding endpoint
- 1.9
CV endpoint
Aspirin4.5 per 100 person-year
Clopidogrel4.5 per 100 person-year
Bleeding endpoint
Aspirin2.0
Clopidogrel1.9
Aspirin vs ClopidogrelHazard ratio (95% CI)P value
CV endpoint
1.00(.77-1.30)
P = 0.97Bleeding endpoint
1.02(.69-1.52)
P = 0.92Further findings
Assigned monotherapy continued at 1 year
Safety
| Outcome | Aspirin | Clopidogrel | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Bleeding endpoint (BARC 3 or 5) · beyond 30 days and up to 1 yearCo-primary endpoint | 2.0 | 1.9 | 1.02 (.69-1.52) | P = 0.92 | |
| 0.512Hazard ratio (log scale) |
Original publication
Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial. Eur Heart J. Published 31 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →